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Abstract Lovastatin (LOV) is widely used for the treat-
ment of hypercholesterolemia. The poor water solubility of
LOV leads to its poor gastrointestinal absorption and
results in poor bioavailability. In this study, a preparation
of solid dispersions with acetylsalicylic acid (ASA) was
studied to improve the dissolution rate of LOV. Solid
dispersions were prepared using various mass ratios of both
components through the grinding method. Differential
scanning calorimetry (DSC), Fourier transform infrared
spectroscopy (FTIR) and X-ray powder diffraction (XRPD)
were used to characterize prepared solid dispersions. Their
dissolution behaviors were also compared. LOV and ASA
formed a simple eutectic phase diagram as indicated by
DSC. The results obtained from FTIR spectroscopy and
XRPD showed no evidence of drug–drug interaction. The
dissolution studies indicated that the in vitro dissolution
rate of LOV released from solid dispersions containing 10,
20, 40 and 60 mass% LOV was improved compared with
the drug alone.
Keywords Lovastatin  Acetylsalicylic acid  Phase
diagram  Dissolution  Solid dispersion  DSC  FTIR 
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Introduction
Lovastatin, an active pharmaceutical ingredient (API) of
drugs widely used for the treatment of hypercholes-
terolemia, is one of the competitive inhibitors of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase [1].
This group of medicines is called statins, which, beyond
their ability to lower serum cholesterol levels, is also known
for their pleiotropic actions independent of lipid-lowering
properties. These effects include improving endothelial
dysfunction, decreasing vascular inflammation, inhibiting
smooth-muscle proliferation and impacting on the coagu-
lation system and fibrinolysis and immunomodulation [2–5].
Lovastatin is also a potent inhibitor of meningioma cell
proliferation [6] and induces a specific apoptotic response in
lung cancer cells within an achievable therapeutic range [7].
Lovastatin protects human endothelial cells from the geno-
toxic and cytotoxic effects of anticancer drugs [8].
Acetylsalicylic acid (ASA), known commonly as
aspirin, prevents the aggregation of platelets and is rec-
ommended at low doses (75–325 mg daily) for patients to
pharmacologically prevent cardiovascular disease besides
an administration of cholesterol-lowering drugs [9, 10].
Combination therapy, in which two or more active phar-
maceutical ingredients (APIs) are contained in a single dosage
form, may cause an improvement in patient compliance and
consequently increase the efficiency of therapy [11, 12]. For
orally administered drugs, solubility is one of the most lim-
iting parameters affecting their bioavailability [13]. Poor
solubility of active ingredients causes great limitation in the
absorption process of a drug. Lovastatin belongs to the II class
of Biopharmaceutics Classification System (BCS) due to its
high permeability and low water solubility (0.4 lg mL-1
[14]). Therefore, it can be assumed that improving its disso-
lution will improve its bioavailability. An effective and
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convenient technique used to enhance the dissolution of
poorly soluble drugs is the preparation of solid dispersion
[15–17]. A lot of carriers have been employed in the prepa-
ration of lovastatin solid dispersions in order to improve the
solubility of LOV, such as mannitol [18], Poloxamer F68
[19], polyethylene glycol 4000 and 6000, (PEG 4000, PEG
6000), polyvinylpyrrolidone K30 (PVP K30) [20, 21], sodium
starch glycolate, croscarmellose sodium, crospovidone [22, 23],
locust bean gum [24] and soluplus [25], but no reports exist
on forming lovastatin solid dispersions with other APIs. Our
previous research into binary mixtures of fenofibrate or
simvastatin with ASA showed an appreciable increase in the
API dissolution rate in relation to eutectic formations
[26, 27]. In light of this, the aim of the present study was to
characterize the solid state of the prepared LOV/ASA solid
dispersions by DSC, FTIR and XRPD, as well as to assess
the formation of LOV/ASA solid dispersions on the disso-
lution rate of both ingredients.
Experimental
Materials
Lovastatin (99 %) was obtained as a gift sample from
Polpharma (Poland). ASA (99 %) was a commercially
available product of Aldrich. Sodium lauryl sulfate (SLS)
was purchased from Stanlab (Poland). Sodium hydrogen
phosphate, potassium dihydrogen phosphate and phospho-
ric acid were purchased from Chempur (Poland). Acetoni-
trile (HPLC grade) was obtained from Fluka Biochemica
(Germany).
Preparation of solid dispersions
Finely powdered mixtures were prepared from accurately
weighed quantities of each component using a Mettler
Toledo AT 261 microbalance (±0.01 mg). Next, the mix-
tures were very thoroughly ground together for at least
10 min using an agate mortar and pestle. DSC studies
confirmed that both components were stable after grinding.
Nine solid dispersions of lovastatin and ASA were pre-
pared. The mass ratios of the LOV/ASA dispersions were
10.0/90.0, 20.0/80.0, 30.0/70, 40.0/60.0, 50.0/50.0, 60.0/
40.0, 70.0/30.0, 80.0/20.0 and 90.0/10.0 %, respectively.
The pulverized mixtures were sieved using a 315-lm sieve
and then stored in a desiccator at room temperature until
use.
Drug content
The aspirin and lovastatin contents of the dispersions were
found to be in the range of 98.19–102.50 % of the declared
amounts. Table 1 lists the results from the investigations of
drugs content in the dispersions.
Differential scanning calorimetry (DSC)
The DSC curves of pure components and solid dispersion
were obtained using a DSC 214 Polyma (Netzsch, Ger-
many) heat flux type calorimeter. Measurement control and
data analysis were performed with Proteus software (Net-
zsch, Germany). Samples for the DSC measurements were
sealed in 40-ll standard aluminum crucibles with a single
hole punched in the lid. The total mass of a sample was
between 4 and 6 mg. An empty crucible of the same type
was used as a reference. The seven-point temperature
calibration was performed using adamantane (-64.5 C),
indium (156.6 C), tin (231.9 C), bismuth (271.4 C) and
zinc (419.5 C) as a standard [28, 29]. The DSC cell was
purged with a stream of high purity nitrogen (99.999 %) at
a rate of 25 cm3 min-1. DSC scans of all dispersions and
pure components were run in triplicate at a heating rate of
10 C min-1 in the temperature range of 25–190 C.
X-Ray powder diffractometry (XRPD)
Powder X-ray diffraction patterns were collected on a D2
Phaser (Bruker, Germany) diffractometer, operating at
30 kV and 10 mA, with a CuKa radiation and LYNXEYE
detector. The powder samples were scanned over a 2h
range of 5–40 with a step size of 0.02 and step time of
0.5 s.
Fourier transform infrared spectroscopy (FTIR)
FTIR spectra were performed on Nicolet iS50 FTIR
(Thermo Scientific, USA) spectrometer by using an atten-
uated total reflection (ATR) module. The spectra were
scanned over a wavenumber range of 4000–400 cm-1.





10/90 LOV/ASA 98.19 ± 0.13 102.39 ± 0.17
20/80 LOV/ASA 99.39 ± 0.35 101.02 ± 0.25
30/70 LOV/ASA 100.41 ± 0.25 99.68 ± 0.20
40/60 LOV/ASA 101.90 ± 0.48 98.27 ± 0.26
50/50 LOV/ASA 101.96 ± 0.24 98.24 ± 0.34
60/40 LOV/ASA 102.50 ± 0.32 98.55 ± 0.17
70/30 LOV/ASA 101.79 ± 0.23 99.89 ± 0.10
80/20 LOV/ASA 102.42 ± 0.15 98.44 ± 0.19
90/10 LOV/ASA 102.10 ± 0.17 98.90 ± 0.35
Data are expressed as mean ± SD (n = 3)
778 A. Go´rniak et al.
123
Intrinsic dissolution rate (IDR)
The intrinsic dissolution rate studies were carried out for
pure LOV and all of the prepared solid dispersions of LOV/
ASA. The dissolution studies were tested in water bath
dissolution SR8-PLUS (Hanson, USA) fitted with a
7-channel peristaltic pump. The intrinsic dissolution rate
was measured using the rotating disk method. LOV
(100.0 mg) or an equivalent amount of solid dispersion
disks were prepared by compressing powder in a Specac
hydraulic press (Mettler Toledo, Switzerland) for 1 min
under 1 t compression force, using a 8-mm punch. The die
was mounted on the stirring drive mechanism and was
rotated at 50 rpm. The dissolution test was conducted
under sink conditions in 1000 mL of pH 7.0 phosphate
buffer with 0.5 % SLS at 37 ± 0.5 C and rotational
speeds of 50 rpm at 37 ± 0.5 C. Samples were withdrawn
at appropriate time intervals. Quantitative determinations
for LOV and ASA were performed with HPLC system
(System GOLD 126, Beckman Coulter) with a UV–Vis
detector. The analysis was carried out with the use of
Zorbax SB-C8 (25 cm 9 4.6 mm, 5 lm, Agilent). HPLC
analyses were performed by isocratic elution with a flow
rate of 1.5 mL min-1. The mobile phase composition was
acetonitrile–water (60:40) with 0.1 % phosphoric acid.
Substances eluted from the column were identified by UV–
Vis detector at 238 nm. External standards of LOV and
ASA were used to obtain calibration curves. Linear cali-
bration curves were obtained between 5 and 300 lg mL-1
for LOV and between 5 and 650 lg mL-1 for ASA.
In vitro of LOV/ASA solid dispersions dissolving
into hard gelatin capsule
Release studies were carried out in triplicate in USP
Apparatus 2 (Basket type). Solid dispersions equivalent to
40 mg of the drug in gelatin capsules were added 500 mL
of pH 7.0 phosphate buffer with 0.5 % SLS stirred at
75 rpm. Aliquots of 3 mL were withdrawn at specified
time intervals and analyzed by HPLC at 238 nm.
Results and discussion
DSC study
The DSC curves of LOV, ASA and investigated disper-
sions obtained at a heating rate of 10 C min-1 in the
temperature range from 25 to 190 C are presented in
Fig. 1. Pure LOV and ASA shows a characteristic endo-
therm peak (DfusH = 101.8 and DfusH = 178.7 J g
-1,
respectively) corresponding to melting points at 173.4 and
145.3 C, respectively. The DSC curves of the various
dispersions indicated that LOV and ASA formed a binary
eutectic system. The phase diagram constructed on the
basis of the DSC results is presented in Fig. 2. The DSC
curves of investigated dispersions, presented in Fig. 1,
demonstrated only two endothermal effects which have an
outline characteristic for simple eutectic systems. The first
sharp peak with a variable area appeared at the same
temperature for all the dispersions, while the second peak

































Fig. 1 DSC curves of: ASA (a), LOV (b) and obtained LOV/ASA
solid dispersions: 90/10 % w/w LOV/ASA (c), 80/20 % w/w LOV/
ASA (d), 70/30 % w/w LOV/ASA (e), 60/40 % w/w LOV/ASA (f),
50/50 % w/w LOV/ASA (g), 40/60 % w/w LOV/ASA (h),
30/70 % w/w LOV/ASA (i), 20/80 % w/w LOV/ASA (j),
10/90 % w/w LOV/ASA (k)
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was wider and appeared at different positions according to
the mass ratios as shown in Fig. 1. The onset of the first
peak near 122.1 C does not vary with the mass ratio of
LOV and indicates the temperature of the eutectic reaction:
solid ASA ? solid LOV = liquid (L). The thermal effect
corresponding to the eutectic reaction was visible on DSC
curves for most dispersions examined (Fig. 1). The values
of the eutectic melting enthalpy DH (J g-1) for a given
dispersions, determined by integration of the eutectic peak
area on DSC curves, are plotted in Fig. 3 versus mass ratio
of LOV in order to construct Tamman’s triangle [30]. The
composition of the eutectic point, corresponding to the
maximum value of enthalpy, has been found for 56.0
mass% of LOV, which is in agreement with the phase
diagram (Fig. 2). The enthalpy of the eutectic transition
goes to zero for compositions corresponding to pure
components. This confirms that there is no mutual
miscibility in the solid state and no formation of terminal
solid solutions at either side of the phase diagram.
XRPD study
The diffraction spectra of LOV, ASA and dispersions with
80/20, 60/40, 40/60 and 20/80 LOV/ASA mass ratios,
respectively, are presented in Fig. 4. The X-ray diffrac-
tograms of pure LOV and ASA shows the crystalline nature
of drugs, as indicated by numerous distinctive peaks.
Characteristic diffraction peaks occurred for LOV at
approximately 2h angles of 7.84, 9.36, 10.12, 10.88,
12.80, 15.60, 16.68, 17.28, 17.76, 18.88, 19.32,
19.68, 22.40, 24.48, 25.12, 25.92, 28.38. The X-ray
diffractogram of ASA shows characteristic distinctive
sharp peaks at a diffraction 2h angle of 7.76 and 15.60,
26.92. The diffractogram of the solid dispersion that
contained 90 mass% of ASA exhibited the presence of
distinctive peaks of crystalline second phase—LOV at 2h
of 9.36, 17.76, 18.88, 19.68, although their relative
intensities were reduced. On the other hand, similar
observations were noted on an X-ray diffractogram of 90
mass% LOV. It shows a slight amount of the crystalline
ASA exhibited on the presence of distinctive peaks at 2h
of: 7.76 and 15.60, 26.92. These data confirmed that at
room temperature the two components which formed the
examined dispersions do not create solid solutions. More-
over, no other peaks than those that could be assigned to
the LOV and ASA were detected in the diffraction patterns
of dispersions, indicating an absence of chemical interac-
tion in the solid state between the two entities.
FTIR study
The FTIR spectra of pure drugs and their dispersions are
presented in Fig. 5. The spectrum of pure LOV shows intense
absorption bands at 3538 cm-1 (alcohol O–H stretching),
3017 cm-1 (olefinic C–H stretching), 2965 cm-1 (methyl
C–H asymmetric stretching), 2929 cm-1 (methylene C–H
asymmetric stretching), 2866 cm-1 (methyl and methylene
C–H asymmetric stretching), 1723, 1697 cm-1 (lactone and
ester carbonyl stretch), 1459 cm-1 (methyl asymmetric
bend), 1381 cm-1 (methyl symmetric bend), 1260 cm-1
(lactone C–O–C asymmetric bend), 1214 cm-1 (ester C–O–C
asymmetric bend), 1074 cm-1 (lactone C–C symmetric
bend), 1054 cm-1 (ester C–O–C symmetric bend), 969 cm-1
(alcohol C–OH stretch) and 870 cm-1 (trisubstituted olefinic
C–H). All major LOV peaks and absorption bands charac-
teristic for ASA at 1604 cm-1 (benzene ring stretching), at
1678 and 1749 cm-1 (aliphatic carbonyls vibrations) and a
broader band at 2500–3500 cm-1 (carboxylic acid hydroxyl
group stretching) appear in the spectra of examined disper-
sions at the same wavenumbers. The spectra show only a








































Fig. 3 Tamman’s triangle construction for the eutectic melting
enthalpy DH at 122.1 C
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reduction in the sharpness of peaks as compared to the spectra
of pure components. The absence of a major shift in the
observed peak positions indicates no interaction in the solid
state between LOV and ASA.
Dissolution studies
In Table 2, the IDR of the pure LOV and its solid dispersions
with ASA in pH 7.0 phosphate buffer with 0.5 % SLS is
summarized. Kaplan noted that compounds with an IDR below
0.1 mg cm-2 min-1 usually exhibit a dissolution rate-limited
absorption [31]. The IDR of pure LOV dissolved to pH 7.0
phosphate buffer with 0.5 % SLS was 0.023 mg cm-2 min-1,
which makes it fall into this category. The intrinsic disso-
lution rate of LOV in solid dispersions containing the sub-
stance by mass percentage from 10, 20, 30, 40 and 50 % was
higher. After 24 h of the test, almost 30 % of LOV was
released from the solid dispersion containing 10 mass% of
LOV, when at this time 16 % of pure LOV had been dis-
solved, as shown in Fig. 6. The dissolution rate of ASA from
solid dispersions in conditions of constant surface area has
not improved as shown in Fig. 7 and even has decreased.
However, after 24 h of the test more than 50 % of ASA was
released from most of the examined dispersions.
















Fig. 4 XRPD patterns of:
ASA (a),
10/90 % w/w LOV/ASA (b),
20/80 % w/w LOV/ASA (c),
40/60 % w/w LOV/ASA (d),
60/40 % w/w LOV/ASA (e),
80/20 % w/w LOV/ASA (f),
90/10 % w/w LOV/ASA (g),
LOV (h)









Fig. 5 FTIR spectra of:
ASA (a),
10/90 % w/w LOV/ASA (b),
30/70 % w/w LOV/ASA (c),
50/50 % w/w LOV/ASA (d),
70/30 % w/w LOV/ASA (e),
90/10 % w/w LOV/ASA (f),
LOV (g)
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In vitro results of LOV and ASA dissolving into a hard
gelatin capsule in pH 7.0 phosphate buffer with 0.5 % SLS
over a period of 60 min are shown in Figs. 8 and 9, respec-
tively. The dissolution rate of LOV from solid dispersions
10/90 LOV/ASA, 20/80 LOV/ASA, 40/60 LOV/ASA and
60/40 LOV/ASA were higher (85.1, 95.6, 59.3 and 60.4 %,
respectively) than that of pure LOV (53.9 %) within 20 min.
The dissolution rate tests carried out by both methods show
that the improvement in the dissolution rate of LOV was
observed for solid dispersions with the LOV mass content
near and below the eutectic composition. The most likely
reason for this was that the progress of dissolution was
determined by the high content of ASA, which improves the
dissolution of LOV and causes it to move more quickly to the
solution. The results obtained allow the development of the
most advantageous combinations in an oral dosage form with
modified physical properties containing both ingredients in
the range of desired therapeutic concentrations, i.e., LOV in
the range of 10–40 mg and 75–100 mg of ASA.
Conclusions
In this study, the grinding method was successfully applied
to obtain solid dispersions of two BCS class II drugs,
lovastatin and ASA. The DSC investigation has revealed
Table 2 Intrinsic dissolution rate (IDR) of pure LOV and prepared
dispersions (SDs), and corresponding ratios
Dispersion IDR/mg cm-2 min-1 r2 IDR ratio
SDs/LOV
10/90 LOV/ASA 0.0400 ± 0.0002 0.9934 1.72
20/80 LOV/ASA 0.0350 ± 0.0001 0.9952 1.52
30/70 LOV/ASA 0.0290 ± 0.0002 0.9964 1.25
40/60 LOV/ASA 0.0280 ± 0.0002 0.9995 1.21
50/50 LOV/ASA 0.0250 ± 0.0007 0.9993 1.07
60/40 LOV/ASA 0.0220 ± 0.0001 0.9994 0.93
70/30 LOV/ASA 0.0210 ± 0.0010 0.9986 0.90
80/20 LOV/ASA 0.0190 ± 0.0004 0.9993 0.82
90/10 LOV/ASA 0.0200 ± 0.0007 0.9997 0.86
LOV 0.0230 ± 0.0004 0.9995 –




































Fig. 6 Dissolved amount of LOV from LOV/ASA solid dispersions
within 24 h of dissolution process compared with pure LOV






































Fig. 7 Dissolved amount of ASA from LOV/ASA solid dispersions



































Fig. 8 Dissolution profiles of LOV from LOV/ASA solid dispersions





































Fig. 9 Dissolution profiles of ASA from LOV/ASA solid dispersions
in the hard gelatin capsules
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that LOV and ASA form a simple eutectic phase diagram.
FTIR spectroscopy and XRPD studies of obtained disper-
sions showed no interaction between the components in the
solid state and confirmed the absence of terminal solid
solutions. The obtained in vitro dissolution results indicate
that the formation of lovastatin solid dispersions with ASA
could be a promising approach to improve its release from
oral dosage form, and hence may affect its bioavailability.
The improvement of the LOV dissolution rate does not
depend directly on a eutectic composition, as in the case of
simvastatin [27], that has water solubility one order of
magnitude better (30 lg mL-1 [32]) than LOV, but the
formation of eutectic in the LOV–ASA system naturally
promotes the effective wetting of the reduced drug particles
released from eutectic composition. The results of our
investigation show that lovastatin dissolution rate can be
improved by the formation of solid dispersions with ASA
without chemical interaction between the drugs. This
method could develop new oral pharmaceutical prepara-
tions with an expanded therapeutic spectrum for the treat-
ment of cardiovascular diseases.
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